MiR155 contributes to impaired T cell-dependent antibody response [18], promotes production of both monocytic and granulocytic MDSCs and induces chemoresistance through C/EBPβ/IL6/IL6R/STAT3 signaling axis in tumor-associated macrophages [19, 20]. Here, IL6 is linked to neoplasm.